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NYHA class: New York Heart Association functional class 
LVEF: left ventricular ejection fraction 
mPCW: mean pulmonary capillary wedge pressure 
MEC: maximal exercise capacity 
HR: heart rate 
BPs: systolic blood pressure 
PP: pulse pressure 
PRP: pressure-rate product 
ESWT: end-systolic wall tension 
ESWT x HR: the product of end-systolic wall tension and heart rate 
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1 
Summary 
Background: 
Several observations suggest that in chronic heart failure when treating patients with 
beta blockers there is correlation between the intermediate-term (5-6 months) change in left 
ventricular function and the long-term change in survival of the patients. These observations 
give crucial importance of the early identification of the subjects, whose reaction in respect of 
the left ventricular function is not favourable to the treatment. By the closer observation of the 
predicted non-responders or by avoiding or modifying beta blocker treatment in such patients 
we can enhance the survival benefit of that therapy. 
Firstly we aimed at elaborating a predictive model to the reliable prediction of the 
intermediate-term effect of bisoprolol on left ventricular ejection fraction, mean pulmonary 
capillary wedge pressure, NYHA functional class, and maximal exercise capacity of patients 
with chronic heart failure. 
Secondly we aimed at validating this model prospectively in a similar, comparable 
group of patients. 
Patients and method: 
The derivation sample, i.e. the group of patients where the predictive model was 
elaborated, consisted of 25 patients (23 men, 2 women) with dilated cardiomyopathy. Their 
mean age was 53.8 ± 15.9 years. Patients had mild or moderate heart failure (NYHA II - III 
class). The validation sample, where the predictive model was prospectively validated, 
consisted of 23 patients (21men, 2 women). Their mean age was 50.4 ± 17.6 years. In both the 
derivation and validation sample on the top of the conventional therapy (ACE-inhibitors, 
directly acting vasodilators, diuretics, digitalis and spironolactone) after an uptitration period 
bisoprolol was given in dose of 7.09 ± 2.14 and 7.24 ± 1.30 mg/day, respectively. As 
candidate parameters for the prediction in the derivation sample baseline values and short-
term (1-month) changes of simple, routinely used, non-invasive parameters were selected. 
Variables proved to be predictive at significant or borderline significant level in univariate 
analysis were evaluated in multivariate analysis as well. Sensitivity and specificity, positive 
and negative predictive accuracy of predictive model were calculated in both derivation and 
validation groups of the patients. 
Aim: 
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Results: 
Prediction of the intermediate-term change in left ventricular ejection fraction was possible 
by two independent parameters: by the left ventricular ejection fraction at baseline and by the 
short-term change in pressure-rate product. Sensitivity of prediction in derivation and 
validation sample was 100 % and 91.7 %, respectively. Specificity in the derivation and 
validation sample was 66.7 % and 70.0 %, respectively. Positive predictive accuracy in 
derivation and validation sample was 80.0 and 78.6 %, respectively. Negative predictive 
accuracy in the two samples was 100.0 and 87,5 %, respectively. 
The short-term change in mean pulmonary capillary wedge pressure was a single predictor of 
the intermediate-term change in mean pulmonary capillary wedge pressure. Sensitivity in 
derivation and validation sample was 85.7 and 84.6 %, respectively. Specificity was 66.7 % in 
both groups of patients. Positive predictive accuracy was 80.0 % in the derivation sample and 
78.6 % in the validation sample. Negative predictive accuracy proved to be 75 % in both 
derivation and validation groups of patients. 
The intermediate-term change in NYHA functional class could be predicted by the baseline 
value of heart rate and NYHA functional class. Sensitivity was in derivation and validation 
sample 83.3 and 82.4 %, respectively. Specificity was found 100 % in the derivation group 
and 80 % in the validation group. Positive predictive accuracy was in derivation and 
validation samples 100.0 and 93.3 %, respectively. Negative predictive accuracy was 62.5 % 
in the derivation group, and 57.1 % in the validation group of patients. 
The 6-month change in maximal exercise capacity was predictable from the baseline value 
of maximal exercise capacity and NYHA functional class. Sensitivity was 80.0 and 75.0 % in 
the derivation and validation group of patients, respectively. Specificity proved to be 25.0 and 
33.3 % in the two patients' groups. Positive predictive accuracy in derivation and validation 
sample was 66.7 and 75.0 %, respectively. And negative predictive accuracy was 40.0 % in 
the derivation sample and 33.3 % in the validation sample. 
Conclusion: 
In moderately severe chronic heart failure simple non-invasive parameters seem to be 
applicable to predict reliably the intermediate-term changes produced by bisoprolol in left 
ventricular ejection fraction and in NYHA functional class. The predictive model can give the 
possibility of the early identification of non-responders. 
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Introduction 
In recent decades there has been a fundamental change in the view of the 
pathophysiology of heart failure. It became clear that the pathologically increased activation 
of the renin-angiotensin-aldosterone and sympathetic nervous system are of overriding 
importance in the progression of the disease. Nowadays, therefore, treatment modalities in 
heart failure are directed towards decreasing pathologically elevated neurohormonal activity 
instead of simple correction of haemodynamic abnormalities. As a consequence of this change 
of view, the treatment with ACE inhibitors and beta blockers in chronic heart failure has been 
introduced. 
Numerous controlled and uncontrolled clinical trials (1-12) have demonstrated the 
beneficial effects of beta blockers on clinical symptoms, left ventricular systolic and diastolic 
function as early as the initial phase of investigation of beta blocker treatment in heart failure. 
However the data for benefit on survival until the last years were only suggestive. Recently four, 
large, multicentre, randomised studies proved the beneficial effect of beta blockers on survival in 
chronic heart failure, as well. The United States Carvedilol Program (USCP) (13), the second 
Cardiac Insufficiency Bisoprolol Study (CIBIS II) (14) and the Metoprolol CR/XL Randomised 
Intervention Trial in Heart Failure (MERIT HF) (15) unequivocally demonstrated the survival 
benefit of carvedilol, bisoprolol and metoprolol, respectively, particularly in the case of patients 
with mild to moderate (NYHA II-III) heart failure. The Carvedilol Prospective Randomised 
Cumulative Survival Trial (COPERNICUS) has also been completed recently; it has been the first 
trial to establish unequivocally the beneficial effects of beta blockers on morbidity and mortality 
of patients with advanced (NYHA IV) heart failure (16). 
Consequently, the question of whether or not to use beta blockers in heart failure has been 
resolved. However, many new questions have been arisen in part by the survival trials themselves 
and in part by the widespread clinical use of beta blockers. 
One of the most important of these problems is which patients do not respond to the 
beta blocker therapy, whether it is possible to select them in advance and if so, how. Even the 
first investigators of the beta blocker treatment in heart failure (1,3,5) had observed that some 
patients with heart failure derive more benefit from beta blocker therapy than others and some 
of them may deteriorate during such treatment. The subgroup analysis of almost every large 
survival trial also identified subgroups, which did not respond favourably to long-term beta 
blocker therapy. 
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The subgroup analysis of the CIBIS I study suggested that patients who had a lower 
baseline left ventricular ejection fraction (< 20 %) responded more favourably to the treatment 
(17). In the CIBIS II study (18) female gender proved to be a positive predictor of survival, in 
contrast with the results of the MERIT trial (15). The Beta Blocker Evaluation Survival Trial 
(BEST) has shown that patients with NYHA Class IV heart failure or an ejection fraction of < 20 
% did not appear to benefit from bucindolol therapy. Men tended to benefit more than women in 
this study and a lack of benefit or even a possible harmful effect was experienced in the African-
American subgroup (19). 
Although the data of the subgroup analysis are contradictory, it is a fact that about 20-50 % 
of patients do not respond sufficiently in every respect; their clinical condition, parameters 
characterising left ventricular function or functional capacity remain unchanged or deteriorate 
(3,5,11,17-18,19-21). The contradictions of the data can be explained by the considerable 
differences in the pharmacological properties of the drugs, by the different doses of beta blockers 
in different studies and by the differences in the groups of patients investigated. 
The really important question is whether the patients who do not respond sufficiently in the 
above respect would be non-responders concerning survival, as well. We have no data about the 
correlation between the changes in NYHA functional class and maximal exercise capacity during 
beta blocker therapy and survival. It seems likely that there is no close correlation between them, 
particularly when applying non-cardioselective drugs. On the other hand the MOCHA trial, the 
subgroup analysis of the Cardiac Insufficiency Bisoprolol Study (CIBIS I) and a controlled 
study by Engelmeier et al. confirm a connection between the effect of beta blocker on left 
ventricular function (mainly on the left ventricular ejection fraction) and its effect on survival 
(5,20,23). 
It seems to be presumable that the therapeutic potential of beta blockers could be further 
enhanced if one could reliably predict before introduction of the drug or in the early treatment 
phase patients who would not respond. Early withdrawal or modification of beta blocker therapy, 
or at least close follow up of the non responders, could further increase the survival benefit. 
Consequently, it is of great importance to find parameters that could predict the effect of 
intermediate-term (5-6 months) beta blocker treatment on left ventricular function, and by this 
means predict the long-term survival before the introduction of the therapy or short-term after 
introduction. 
Efforts to identify responders with respect to the left ventricular function or to different 
improvement indexes based on a combination of clinical variables, left ventricular function and 
eventually exercise parameters have provided partly conflicting results. In most, but not all, 
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studies the haemodynamic consequences of increased sympathetic activity, such as elevated 
baseline heart rate and its high value at maximal exercise as well as pronounced heart rate changes 
over time after beta-blockade proved to be reliable predictors of a favourable effect of beta 
blockers (1,5,12-13,20-22,24-25). Some studies showed that if the underlying disease is dilated 
cardiomyopathy, one can presume a more favourable response than in the case of ischaemic heart 
disease (6,12). Higher systolic blood pressure at baseline or hypertension in the case history of the 
patient was also reported to be a predictor of beneficial effect (21,26). The clinical severity of 
heart failure, baseline level of left ventricular ejection fraction and diastolic function proved to be 
predictive in some studies as well (3,5,21,26). The extent and dominant type of myocardial 
fibrosis were also suggested as having an influence on the change in NYHA functional class and 
in the left ventricular ejection fraction after 12 months (27). 
In spite of previous attempts, there are still no prospective validated data verified to be 
parameters making the prediction of the effect of beta blocker therapy possible. 
In our previous study (28), we tried to predict the beneficial effect of bisoprolol on systolic 
and diastolic left ventricular function in a group of 25 patients with dilated cardiomyopathy. As 
regards 6-month changes in left ventricular ejection fraction, the baseline value of left ventricular 
ejection fraction and short-term changes in pulse pressure and pressure-rate product proved to be 
predictive. The 6-month changes in mean pulmonary capillary wedge pressure could be predicted 
most exactly by the baseline value of mean pulmonary capillary wedge pressure, the baseline 
heart rate and the increase in heart rate during maximal exercise. 
The aim of this study was to validate prospectively the results of our above-
mentioned investigation, because this is an essential precondition of practical applicability of 
every predictive model (29). The prospective validation of the results has been done in a 
group of patients (validation sample) formed from March 1999. However, in addition to 
diuretics, ACE inhibitors and directly acting vasodilators, all these patients were treated with 
low dose of spironolactone as well before the introduction of beta blocker, on the basis of the 
preliminary results (B. Pitt, AHA Nov 1998) of the RALES study (30). Because only 12 
patients were treated with spironolactone in the previously investigated group of patients, the 
comparability of the two groups became questionable. Therefore in this study we assessed the 
data of those 12 patients - from our previously investigated group of patients - who were 
treated with spironolactone before the introduction of bisoprolol. An additional 13 patients 
were included in the study from patients referred to our clinic between January 1995 and 
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April 1997, who fulfilled the inclusion and exclusion criteria of the study and had been treated 
with low dose of spironolactone in addition to optimal doses of ACE inhibitor, digitalis, 
diuretics and directly acting vasodilators. These 25 patients composed the derivation group 
of the study, in which it was investigated retrospectively whether simple, non-invasive, routinely 
used clinical variables at baseline and in the early treatment phase could predict the intermediate-
term effects (5-6 months) of bisoprolol on left ventricular systolic and diastolic function, 
clinical condition and exercise capacity. 
The clinical utilisation of these predictive factors was prospectively validated on a similar 
group of patients (validation sample). 
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Pharmacological and pharmacokinetic properties of bisoprolol 
Bisoprolol investigated in this study is one of the most selective Pi receptor antagonists. 
Bisoprolol has no intrinsic sympathomimetic activity and has no membrane-stabilising activity in 
therapeutically applied doses. Bisoprolol does not possess vasodilator property. Bisoprolol 
occupies a middle position as regards hydrophilia and lipophilic 
Bisoprolol has a long duration of action. Elimination half-life is 10-12 hours, meaning that 
bisoprolol may be administered once daily. The high absorption rate (> 90 %) and small first-pass 
effect result in an absolute bioavailability of 88 %. Bisoprolol has a "balanced clearance", half of 
the dose is metabolised to inactive metabolites in the liver and the other half is excreted as the 
unchanged substance via the kidneys. 
Acute haemodynamic effects of bisoprolol correspond to the Pi adrenoreceptor blockade: dose-
dependent decrease in heart rate, in blood pressure, in pressure-rate product, in contractility 
and cardiac index. Bisoprolol decreases the exercise-induced increase in heart rate and 
increases the peripheral resistance at the beginning of the administration. 
In the therapeutically recommended doses bisoprolol is nearly devoid of any P2 
adrenoreceptor antagonistic activity and has therefore no effects on p2 adrenoreceptor-
mediated metabolic effects. Bisoprolol induces no change in the cholesterol fractions in long-
term therapy and has no influence on the carbohydrate metabolism. 
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Methods 
Subjects 
The derivation sample consisted of 25 patients (23 men, 2 women) with idiopathic dilated 
cardiomyopathy referred to our clinic between February 1994 and April 1997. In the validation 
sample we investigated 23 patients (21 men, 2 women) with idiopathic dilated cardiomyopathy, 
selected from patients referred to our clinic between March 1999 and December 2000. 
Inclusion criteria (in both the derivation and validation group of patients): 
- Patients had to have a diagnosis of dilated cardiomyopathy. Diagnostic criteria proposed by 
the WHO/ISFC Task Force (31) were applied. Coronary angiography was performed in 9 
cases in the derivation sample and in 8 cases in the validation sample to exclude coronary 
artery disease suggested by the presence of risk factors, chest pain or both. 
- Symptoms had to include dyspnoe on exertion and fatigue corresponding to class II or III of 
the New York Heart Association (NYHA). 
- Patients only with a history of heart failure longer than one year were included. 
- Eligible patients were aged 20-75 years. 
- Left ventricular ejection fraction assessed by two-dimensional transthoracic echocardiography 
was lower than 40 % in every case. 
- Patients only with a resting heart rate higher than 70 beats/min, and systolic blood pressure 
higher than 90 mmHg were enrolled into the study. 
- Patients had to be in stable clinical condition for at least 4 weeks prior to enrolment into the 
study. 
Previous tailored therapy with diuretics, digitalis, ACE inhibitors, nitrate, dihydralazine, low 
dose of spironolactone had to be used for at least 3 months before introduction of bisoprolol. 
The doses of the indicated drugs had to be unchanged during the last 3 weeks before the 
initiation of treatment with bisoprolol. 
- Informed consent was obtained from all patients. 
Exclusion criteria (in both the derivation and validation group of patients): 
- Major contraindications for beta blocker therapy such as chronic obstructive airways disease, 
unstable insulin-dependent diabetes mellitus, advanced AV block (higher than 1st degree) and 
sick sinus syndrome were criteria for exclusion. 
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- Prior beta blocker treatment and alcohol intake greater than 100 g/day in the previous year 
were exclusion criteria, as well. 
Introduction of bisoprolol: The first dose of bisoprolol was 1.25 mg/day, which was uptitrated 
by doubling the dose twice a week or in case of more severe heart failure (NYHA class III), once 
a week, up to 10 mg/day. Patients received less than 10 mg if their systolic blood pressure 
decreased below 80 mmHg or if their resting heart rate was lower than 60 beats/min or when 
persistent progression in heart failure symptoms appeared. At the end of the titration the mean 
dose of bisoprolol was 7.09 + 2.14 mg/day in the derivation sample, and 7.24 ± 1.30 mg/day in 
the validation sample. Every patient remained on these doses after the titration phase. 
One of the patients in the derivation sample did not tolerate the first dose due to 
symptomatic hypotension and significant progression of heart failure. 
In the derivation sample one patient died (sudden death) during the titration phase. In the 
validation sample also one patient died after the titration phase, during the drug maintenance, due 
to progression in heart failure. 
The data of these three patients were not taken into consideration. Only data of patients 
whose prediction investigation could be performed from beginning to end were evaluated. 
Measurements 
Patients underwent clinical and non-invasive cardiac evaluation before the introduction of 
bisoprolol. During the drug maintenance they were re-evaluated at one month and at 6 months 
after starting the treatment. Apart from physical examination the evaluated parameters were 
derived from routinely used non-invasive investigations (electrocardiography, M-mode and 2D 
transthoracic echocardiography, left ventricular apexcardiography and exercise testing). 
The one-month effect of bisoprolol was considered as short-term effect. The short-term 
change in parameters was defined as the change in variables during the first month of treatment. 
The 6-month effect of bisoprolol was considered as intermediate-term effect. The intermediate-
term change in parameters was defined as the change in value of parameters observed from 
baseline to 6 months. 
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Parameters to be predicted (outcome events) 
The intermediate-term changes of the following parameters were investigated and an 
attempt was made to predict them: clinical severity of heart failure (NYHA class), maximal 
exercise capacity (MEC), left ventricular ejection fraction (LVEF) and pulmonary capillary 
wedge pressure (mPCW). The changes were classified into two categories: improvement or lack 
of improvement (parameters unchanged or deteriorated). The changes were expressed as a 
percentage of baseline values. 
The change in left ventricular ejection fraction on 6 months of bisoprolol treatment in the 
case of an individual patient was considered as an improvement if the increase in left ventricular 
ejection fraction was more than 20 % of the baseline value. (It a little bit exceeds the interobserver 
variability (17.5 %) found in our laboratory, when left ventricular ejection fraction was measured 
by 2D echocardiography.) Deterioration was established when the decrease in the left ventricular 
ejection fraction was more than 20 % of the baseline value. The parameter was unchanged if 
neither increase nor decrease was more than 20 % of the baseline value. 
The change in mean pulmonary capillary wedge pressure on 6 months of therapy in an 
individual patient was considered as an improvement if the decrease in pulmonary capillary 
wedge pressure was more than 20 % of the baseline value. (This value was a slightly higher than 
the interobserver variability (18.6 %) found in our laboratory, when pulmonary capillary wedge 
pressure was estimated by measuring diastolic rapid filling period from apexcardiography.) 
Deterioration was established when the increase in the pulmonary capillary wedge pressure was 
more than 20 % of the baseline value. The parameter was unchanged if neither its increase nor 
decrease was more than 20 % of the baseline value. 
An improvement in NYHA functional class on 6 months in an individual patient was 
defined as a decrease in the value of NYHA class of more than or equal to 0.5. Deterioration was 
established when the increase in NYHA functional class was more than or equal to 0.5. The 
parameter was considered as unchanged if neither increase nor decrease was established. 
The change in maximal exercise capacity on 6 months of bisoprolol therapy in an 
individual patient was considered as an improvement if the increase in maximal exercise capacity 
was more than 25 % of the baseline value. (It exceeds a bit the interobserver variability (24 %) of 
the three consecutive measurements of the maximal exercise capacity in the case of 10 patients 
with unchanged clinical condition and on the same therapy.) Deterioration was established when 
the decrease in maximal exercise capacity was more than 25 % of the baseline value. The 
parameter was unchanged if neither increase nor decrease was more than 25 % of the baseline 
value. 
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Candidate predictive parameters: 
To predict the 6 months effect of bisoprolol, baseline values and short-term changes of 
resting and exercise variables were selected as candidate predictors. 
The resting variables were as follows: heart rate (HR), systolic blood pressure (BPs), 
pressure-rate product (PRP) = HR x BPs, pulse pressure (PP) = systolic blood pressure - diastolic 
blood pressure, NYHA functional class, left ventricular ejection fraction, mean pulmonary 
capillary wedge pressure, end-systolic wall tension (ESWT) and the product of end-systolic wall 
tension and heart rate (ESWT x HR). 
The exercise variables were the following: maximal exercise capacity (MEC), heart rate at 
30 W load (HR30W) heart rate at maximal level of exercise (HRmax), the increase in heart rate 
from rest to 30 W load (AHR30W), the increase in heart rate from rest to maximal level of 
exercise (AHRmax), systolic blood pressure at 30 W load (BP30W), systolic blood pressure at 
maximal level of exercise (BPmax), the increase in systolic blood pressure from rest to 30 W load 
(ABP30W), the increase in systolic blood pressure from rest to maximal level of exercise 
(ABPmax). 
Measurement and calculation of the parameters studied: Heart rate was assessed from 
the ECG recordings. Blood pressure was measured in sitting position, using a 
sphygmomanometer. NYHA functional class was evaluated by two independent investigators. In 
the case of difference in opinions it was calculated as mean value. Left ventricular ejection 
fraction was calculated by two-dimensional echocardiographic studies from the apical four-
chamber view using an area-length singe-plane method (Simpson method). Pulmonary capillary 
wedge pressure was estimated by left ventricular apexcardiography from the diastolic rapid filling 
period, by using a previously described method (32,33). End-systolic wall tension was calculated 
by Laplace's low according to Quinones (ESWT = BPs x ESD/(PW + IVS), (ESD: end-systolic 
diameter of left ventricle; PW: posterior wall thickness; IVS: interventricular septal thickness) 
(34). 
Exercise test variables were derived from graded, symptom-limited maximal (estimated 
with the use of the Borg perceived exercise scale) upright bicycle ergometer tests. The tests 
started at 30 W load, the load was increased by 30 W after every three minutes. ECG was 
recorded during the test continuously. Heart rate and blood pressure measurements were carried 
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out every minute. Before baseline testing, a test was done to familiarise the patients with the 
procedure. 
The measurements and calculations of NYHA functional class, left ventricular ejection 
fraction, mean pulmonary capillary wedge pressure and MEC after 6 months of bisoprolol 
treatment were performed by investigators who were blinded in the baseline and short-term values 
of parameters in the case of every patient. 
Statistical analysis 
The baseline characteristics of the derivation and validation samples were compared with 
use of the unpaired Student's t-test. In both the derivation and validation group the differences 
between variables at baseline and at 1 and 6 months were determined by a standard paired 
Student's t-test. To investigate the predictability of the 6-month effect of bisoprolol, the 
intermediate-term changes of left ventricular ejection fraction, pulmonary capillary wedge 
pressure, NYHA functional class and maximal exercise capacity - as a percentage of baseline 
values - were compared with the baseline values and short-term changes of the selected possible 
predictors applying univariate regression analysis. After determination of the predictors by 
univariate analysis, the most significant predictors (p < 0.1) were subjected to analysis by multiple 
regression to assess the relative contribution of each predictor. The probability of improvement in 
an individual subject in respect of a given parameter was modelled by the multiple regression 
model (35) applying the constant and the values of coefficient B. 
Applying correlation derived from the derivation sample, all predicted variables were 
determined in the case of all patients of the validation sample. Then all predicted and observed 
values of 6-month changes in left ventricular ejection fraction, pulmonary capillary wedge 
pressure, NYHA functional class and maximal exercise capacity were compared in the validation 
group of patients. To validate prospectively the correlation derived from the derivation sample, 
the sensitivity, specificity, positive and negative predictive accuracy of this predictive model were 
determined in the validation group. 
Statistical analysis was performed with the SPSS 9.0 program package. Significance was 
taken as p<0.05. All p values were two-sided. All data are reported as mean ± SD. Interobserver 
variability was considered as the double the standard deviation of mean values of differences of 
measurements. 
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Results 
The clinical effect of bisoprolol in the derivation and validation samples 
The clinical characteristics of the derivation and validation samples at baseline are shown 
in Table 1. The two groups were comparable in respect of all investigated variables; there was no 
significant difference between these parameters. 
In both the derivation and validation groups of patients the changes characterising the 
effect of beta-blockade in heart failure could be observed (7able 2a, 2b). 
Heart rate decreased markedly and significantly in both groups of patients at short-term 
and remained at that level at intermediate-term (in the derivation sample: 90.9 ± 17.0 —» 67.2 
± 9.4 -» 62.6 ± 10.6 min"1; in the validation sample: 93.4 ± 15.7 66.9 ± 10.8 65.5 ± 11.2 
min'1). Systolic blood pressure decreased in both groups at 1 month although it was not 
significant, and increased above the baseline at intermediate-term and this increase proved to 
be significant compared to baseline (in the derivation sample: 110.3 ± 17.7 —» 104.1 ± 11.2 —» 
118.8 ± 13.6 mmHg; in the validation sample: 105.4 ± 15.5 100.8 ± 9.3 -» 114.5 ±16.2 
mmHg). The pulse pressure showed the same pattern of changes in the derivation group of 
patients: it decreased at short-term and increased above the baseline at intermediate-term 
(35.6 ± 8.5 33.5 ± 9.3 -» 42.4 ±11.1 mmHg). However, in the validation sample a slight 
increase in pulse pressure was observed after one month, which became significant at 6 
months (30.3 ± 8.9 31.4 ±10.1 40.9 ± 10.4 mmHg). The changes in pressure-rate 
product were similar in the two groups of patients, it decreased markedly and significantly at 
short-term, and moderately increased at intermediate-term (in the derivation sample: 9952.9 ± 
2137.7 6980.6 ± 1152.4 7199.4 ± 1400.5 mmHg x min"1; in the validation sample: 
9885.0 ± 1930.1 6725.4 ± 1240.7 -» 7232.6 ± 1434.5 mmHg x min"1). There was a 
significant improvement in NYHA class (in the derivation sample: 2.47 ± 0.45 2.06 ± 0.58 
-» 1.68 ± 0.47; in the validation sample: 2.53 ± 0.34 2.14 ± 0.48 1.74 ± 0.36) and in 
maximal exercise capacity (in the derivation sample: 49.7 ± 25.7 -» 60.2 ± 27.3 -» 75.9 ± 
35.8 kJ; in the validation sample: 51.3 ± 28.2 65.9 ± 25.9 74.6 ± 35.2 kJ) already at 
short-term and further improvement was observed at intermediate-term. While the decrease in 
mean pulmonary capillary wedge pressure (in the derivation sample: 19.3 ± 7.5 —» 16.3 ± 9.7 
13.8 ± 7.2 mmHg; in the validation sample: 20.5 ± 8.3 —> 18.1 ± 8.8 -» 14.4 ± 6.4 mmHg) 
and the increase in left ventricular ejection fraction (in the derivation sample: 32.6 ± 6.4 —» 
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34.2 ± 9.9 42.6 ± 10.1 %, in the validation sample: 30.8 ± 6.5 33.8 ± 9.9 -> 41.6 ± 9.5 
%) did not reach the level of significance at short-term, at intermediate-term beneficial 
changes in parameters became marked and significant. 
The increase in heart rate at maximal level of exercise increased slightly in both groups at 6 
months, but this increase was not considerable in either derivation or validation group (in the 
derivation sample: 55.5 ± 22.9 54.4 ±21.3 —> 58.3 ± 23.1 min'1, in the validation sample: 
49.3 ± 22.8 47.9 ± 21.4 -> 54.2 ± 23.2 min"1). End-systolic wall tension decreased in both 
groups at short-term. The change in the derivation sample was not significant, while in the 
validation sample it proved borderline significant. Compared to its decrease at one month the 
further decrease was not substantial during the later period of the observation in either group 
of the patients (in the derivation sample: 323.0 ± 135.0 271.7 ± 57.7 -> 284.1 ± 162.4 
mmHg, in the validation sample: 299.3 ± 64.7 -» 269.8 ± 59.3 256.4 ± 82.9 mmHg). 
However, the product of end-systolic wall tension and heart rate decreased significantly and 
markedly already at short-term and a further decrease was observed at intermediate-term in 
both groups of patients (in the derivation sample: 28930.4 ± 11696.0 18132.4 ± 3998.2 -> 
17609.4 ± 9675.0 mmHg x min"1, in validation sample: 27166.6 ± 6349.5 17843.2 ± 
3982.3 16017.8 ± 5944.4 mmHg x min"1). 
Predictors of intermediate-term changes in left ventricular ejection fraction, 
pulmonary capillary wedge pressure, NYHA functional class and in maximal 
exercise capacity in the DERIVATION SAMPLE 
In the derivation group of patients after six months of bisoprolol treatment the changes 
in the parameters to be predicted are shown in Table 3. (The change in NYHA class was 
expressed in absolute value, while the changes in other parameters were expressed as a 
percentage of the baseline value.) 
At intermediate-term the patients were improving clinically, their NYHA functional 
class decreased significantly (p<0.001) from 2.47 to 1.68, the mean value of the decrease was 
0.79 NYHA class. The clinical grade of heart failure did not improve in 5 cases, in 3 cases 
was unchanged and in 2 cases deteriorated. 
The left ventricular ejection fraction improved significantly (p<0.005) from 32.6 to 42.6 %, 
the mean value of the increase was 37.0 % of the baseline value. However there were 8 
patients whose ejection fraction did not change (the changes in the left ventricular ejection 
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fraction were not more than 20 % of the baseline value). In the case of 3 patients deterioration 
was observed in the ejection fraction (i.e. the decrease in ejection fraction was more than 20 
% of the baseline value). 
Similarly, significant changes were seen in the mean pulmonary capillary wedge pressure; it 
decreased from 19.3 to 13.8 mmHg (p<0.005), as well as in the maximal exercise capacity, 
which increased from 49.7 to 75.9 kJ (p<0.001). The mean value of the decrease in 
pulmonary capillary wedge pressure was 28.8 % and the mean value of the increase in 
maximal exercise capacity was 73.6 % of their baseline values. However, there were non-
responders in regard to the latter parameters as well. The pulmonary capillary wedge pressure 
increased more than 20 % compared to baseline in one patient and was considered unchanged 
in 8 patients (i.e. the changes in pulmonary capillary wedge pressure were not more than 20 % 
of baseline value). The maximal exercise capacity was unchanged in 8 patients (i.e. the 
changes were not more than 20 % of the baseline value). 
Table 4 lists the results of the univariate regression analysis in the derivation sample. 
For each parameter to be predicted we have indicated only the predictive variables which 
showed significant or borderline significant (p < 0.1) relation to them. 
Table 4 shows that the intermediate-term change in the left ventricular ejection fraction 
in terms of the percent of baseline value was shown to be in significant relation to the baseline 
value of left ventricular ejection fraction (r = -0.57, p < 0.05) and in borderline significant 
relation to the short-term changes of pulse pressure (r = -0.41, p = 0.1) and that of the 
pressure-rate product (r = -0.41, p = 0.1). This correlation suggests that in treating patients 
with bisoprolol on intermediate-term the lower the baseline value of left ventricular ejection 
fraction and the greater the short-term decrease in the pulse pressure and pressure-rate 
product, the more marked the improvement that can be expected in left ventricular ejection 
fraction. 
The baseline value of end-systolic wall tension and the short-term changes in mean 
pulmonary capillary wedge pressure proved to be significant univariate predictors (r = -0.56, 
p < 0.05; r = 0.52, p < 0.05, respectively) of the intermediate-term changes of mean 
pulmonary capillary wedge pressure. A borderline significant correlation could be 
demonstrated between the intermediate-term changes in mean pulmonary capillary wedge 
pressure and the baseline values of the product of the end-systolic wall tension and heart rate 
(r = - 0.50, p = 0.06), and the short-term changes in the end-systolic wall tension (r = 0.46, p = 
0.08) and that of the product of end-systolic wall tension and heart rate (r = 0.49, p 
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Accordingly, the greatest improvement in mean pulmonary capillary wedge pressure after 6 
months of bisoprolol treatment can be expected in cases where the baseline value of the end-
systolic wall tension, and the product of end-systolic wall tension and heart rate is high, and 
the short-term decrease of mean pulmonary capillary wedge pressure, end-systolic wall 
tension and the product of end-systolic wall tension and heart rate is pronounced. 
Alteration in NYHA functional class was predictable from its baseline value (r = -0.66, 
p < 0.005) and from the baseline value of the resting heart rate (r = -0.58, p < 0.05). So the 
chance of improvement in NYHA class at intermediate-term is the greatest when heart failure 
is more severe and when heart rate is high at baseline. 
The intermediate-term changes of the maximal exercise capacity correlated 
significantly with the baseline value of NYHA functional class (r = 0.57, p < 0.05), maximal 
exercise capacity (r = -0.56, p < 0.05) and mean pulmonary capillary wedge pressure (r = 
0.55, p < 0.05). Accordingly the higher the baseline value of NYHA functional class and 
mean pulmonary capillary wedge pressure, and the lower the baseline value of maximal 
exercise capacity the more marked the improvement in maximal exercise capacity at 
intermediate-term. 
The results of the multiple regression analysis are shown in Table 5. 
The baseline value of left ventricular ejection fraction (B = -3.001, p = 0.002), and the 
short-term decrease in the pressure-rate product (B = -0.0099, p = 0.012) were found to be 
independent predictors of intermediate-term changes of left ventricular ejection fraction. 
Accordingly, the lower the left ventricular ejection fraction at baseline and the more 
pronounced the decrease in the pressure-rate product at short-term the more considerable the 
improvement in the left ventricular ejection fraction at intermediate-term. 
Based on these data, in an individual patient the predicted changes of left ventricular ejection 
fraction after 6 months of treatment with bisoprolol could be calculated by the following 
equation: ALVEF% = 105.558 - 3.001 x LVEFa - 0.0099 x APRPb (abbreviations used are 
indicated in Table 5). 
The change in the mean pulmonary capillary wedge pressure related significantly only 
to the short-term change in mean pulmonary capillary wedge pressure (B = 2.400, p = 0.046). 
This means that the more marked the decrease in the mean pulmonary capillary wedge 
pressure at short-term the more pronounced the improvement in the mean pulmonary capillary 
wedge pressure at intermediate-term. 
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The value of intermediate-term change in the mean pulmonary capillary wedge pressure in an 
individual patient could be predicted by the following equation: AmPCW% = -21.319 + 
2.400 x mPCWb (abbreviations used are indicated in Table 5). 
When the multivariate analysis was applied to the prediction of intermediate-term 
change in NYHA functional class, the baseline value of heart rate (B = -0.014, p = 0.072), 
and that of NYHA functional class (B = -0.692, p = 0.021) proved to be an independent 
predictor. Thus the higher the baseline value of heart rate and the more severe the clinical 
condition of the patient at baseline the more substantial the improvement in NYHA functional 
class at intermediate-term. 
The equation for the calculation of intermediate-term changes in NYHA functional class in an 
individual subject was the following: ANYHAclass = 2.164 - 0.014 x HRa - 0.692 
NYHAclass" (abbreviations used are indicated in Table 5). 
According to the result of the multiple regression analysis, the baseline value of 
maximal exercise capacity (B = -1.159, p = 0.138) and that of NYHA functional class (B = 
68.427, p = 0.125) proved to be independent predictors of intermediate-term change in 
maximal exercise capacity. This means that the lower the baseline value of maximal exercise 
capacity and the more severe the clinical condition characterised by NYHA functional class at 
baseline, the more marked the improvement in maximal exercise capacity at intermediate-
term. 
The following equation determined the intermediate-term change in maximal exercise 
capacity in an individual patient: AMEC% = -37.802 + 68.427 x NYHAclass" - 1.159 x 
MECa (abbreviations used are indicated in Table 5). 
The data described formerly show, that in the derivation sample we could find simple, 
non-invasive, routinely used variables which can predict the 6 months changes in parameters 
of crucial importance during bisoprolol treatment before the introduction of the drug or 
shortly after. 
To control the predictive model we used, the predicted values of the parameters (outcome 
events) were determined for each patient of the derivation group applying the above-
mentioned equations. In a next step predicted and observed values of these parameters were 
compared and sensitivity, specificity, positive and negative predictive accuracy of the 
predictive model was tested (Table 6). 
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Outstandingly high sensitivity (100 %) and negative predictive accuracy (100 %) was 
found in the case of left ventricular ejection fraction. That the sensitivity is one hundred 
percent means that the applied predictive model could predict the improvement in left 
ventricular ejection fraction for all patients whose left ventricular ejection fraction really 
improved after 6 months of bisoprolol treatment. That the negative predictive accuracy is one 
hundred percent means that the left ventricular ejection fraction in all patients whose left 
ventricular ejection fraction was predicted to be unchanged or deteriorated was really 
unchanged or deteriorated at the end of 6 months of treatment. In addition to the outstandingly 
high value of sensitivity and negative predictive accuracy, acceptable specificity (66.7 %) and 
positive predictive accuracy (80 %) were found as well. When predicting the intermediate-
term change in left ventricular ejection fraction a mistake in prediction occurred in only 3 
cases (total error rate: 13 %), when instead of not improvement an improvement was 
predicted. Thus the predictive model applied in this study makes possible reliable prediction 
concerning left ventricular ejection fraction. 
The close correlation (r = 0.76, p < 0.001) between observed and predicted changes in left 
ventricular ejection fraction at 6-month therapy with bisoprolol in the derivation group of 
patients is illustrated in Figure 1/a. 
In the case of mean pulmonary capillary wedge pressure we could calculate high 
sensitivity (85.7 %), acceptable specificity (66.7 %), high positive predictive accuracy (80 
%) and a little lower negative predictive accuracy (75 %). That the positive predictive 
accuracy is 80 % means that the mean pulmonary capillary wedge pressure of 80 % of 
patients whose mean pulmonary capillary wedge pressure was predicted to be improved by 
our predictive model really improved at 6-month bisoprolol treatment. That the negative 
predictive accuracy is 75 % means that in 75 % of patients whose mean pulmonary capillary 
wedge pressure was predicted to be unchanged or deteriorated the observed value of mean 
pulmonary capillary wedge pressure was really unchanged or deteriorated after intermediate-
term treatment with bisoprolol. Although this can be regarded as quite good prediction (total 
error rate: 21.7 %), nevertheless we have to be cautious when our therapeutical decision is 
based on this prediction. 
The moderate correlation (r = 0.52, p < 0.05) between predicted and observed changes in 
pulmonary capillary wedge pressure at 6-month of bisoprolol treatment in derivation sample 
is showed in Figure 2/a. 
As for NYHA functional class, specificity was 100 %, accordingly positive predictive 
accuracy was also 100 %, sensitivity was 83.3 % and negative predictive accuracy was 62.5 
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%. This means that false positive cases were not found. Thus all 15 patients whose clinical 
condition was predicted to improve really improved after 6 months of bisoprolol therapy, 
while of the patients whose clinical status was predicted not to improve, 5 really deteriorated 
or were unchanged, but 3 patients improved. 
The predictive model applied in this study makes reliable prediction possible concerning 
NYHA functional class. This accuracy is similar but different in meaning from that found in 
the case of left ventricular ejection fraction. The total error rate was only 13 %. 
After 6-month therapy with bisoprolol the close correlation (r = 0.74, p < 0.001) between 
observed and predicted changes of NYHA functional class can be seen in Figure 3/a. 
In the case of maximal exercise capacity there was found an acceptable sensitivity 
(80 %), a very low specificity (25 %), a moderate positive predictive accuracy (66.7 %), and 
a low negative predictive accuracy (40 %). This means that the prediction of the 
improvement of maximal exercise capacity was accurate enough, meanwhile the prediction of 
the no improvement proved to be fairly uncertain. As a consequence in the case of 9 out of 23 
patients the intermediate-term changes in maximal exercise capacity were predicted 
inaccurately, the total error rate was 39 %. 
In the derivation group of patients the moderate correlation (r = 0.66, p < 0.001) between 
observed and predicted changes in maximal exercise capacity at 6-month treatment with 
bisoprolol is demonstrated in Figure 4/a. 
Prospective validation 
In patients of the validation sample, before the introduction of bisoprolol and 1 month 
later the expected 6 months changes in every outcome parameter (left ventricular ejection 
fraction, mean pulmonary capillary wedge pressure, NYHA functional class, maximal 
exercise capacity) were predicted by equations derived from multiple regression analysis in 
the derivation sample. After 6 months the predicted and observed changes in investigated 
parameters were compared. 
The results derived from the validation sample were similar to those obtained from the 
derivation sample. 
Regarding the left ventricular ejection fraction we did find high sensitivity (91.7 %), 
moderate specificity (70 %), good positive predictive accuracy (78.6 %), and high negative 
predictive accuracy (87.5 %). This means that of the patients whose left ventricular ejection 
fraction was predicted not to improve, the left ventricular ejection fraction of 7 out of 8 
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patients really deteriorated or were unchanged, while 11 out of 14 patients whose left 
ventricular ejection fraction was predicted to improve it really improved. This is regarded as 
good prediction concerning both the improvement and particularly the no improvement; these 
results are similar to those found in the derivation sample. 
In the validation sample the close correlation (r = 0.73, p < 0.001) between observed and 
predicted changes in left ventricular ejection fraction after 6 month treatment with bisoprolol 
is illustrated in Figure 1/b. 
In the case of mean pulmonary capillary wedge pressure, sensitivity was 84.6 %, 
specificity was 66.7 %, positive predictive accuracy was 78.6 %, and negative predictive 
accuracy was 75 %. This means that in 75 % of the patients whose mean pulmonary capillary 
wedge pressure was predicted not to improve it really deteriorated or were unchanged, while 
11 out of 14 patients whose mean pulmonary capillary wedge pressure was predicted to 
improve the mean pulmonary capillary wedge pressure really improved. Accordingly, the 6-
month changes in pulmonary capillary wedge pressure in the validation sample could be 
predicted adequately by the prediction rule derived from the derivation sample. But accuracy 
of prediction was lower than in the case of left ventricular ejection fraction. 
The moderate (r = 0.62, p <0.01) correlation between observed and predicted changes in 
pulmonary capillary wedge pressure during 6-month bisoprolol therapy in the validation 
group of patients can be seen in Figure 2/b. 
The reliable predictability of the 6 months changes in NYHA functional class is 
reflected by the high value of the sensitivity (82.4 %) and specificity (80 %). The positive 
(93.3 %) and negative predictive accuracy (57.1 %) shows that this predictive model is 
applicable much more reliably to identify the patients whose clinical condition will improve. 
Figure 3/b shows the close correlation (r = 0.73, p <0.001) between observed and predicted 
changes in NYHA functional class at 6-month treatment with bisoprolol in the validation 
sample. 
As for maximal exercise capacity there were good sensitivity (75 %) and positive 
predictive accuracy (75 %), however both the specificity and negative predictive accuracy 
were only 33.3 %. This means that the predictability of the no improvement in maximal 
exercise capacity is quite uncertain, similarly to what was found in the derivation sample. 
Moderate correlation (r = 0.65, p < 0.01) between observed and predicted changes in maximal 
exercise capacity during 6-month therapy with bisoprolol in the validation group of patients 
was illustrated in Figure 4/b. 
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Discussion 
Using beta-adrenergic blockers in the treatment of chronic heart failure is one of the 
largest breakthroughs in cardiology in recent decades. While until recently, beta blockers were 
considered contraindicated for use in patients with heart failure, now these drugs are one of the 
most important tools in the treatment of heart failure. Beta receptor blocker therapy represents the 
substantial change in our approach to therapy. Nowadays the aim of the treatment of heart failure 
is not to obtain short-term success with the rapid correction of haemodynamic condition but to 
influence beneficially the prognosis of heart failure by favourable alteration the biological 
properties of the failing heart, even at the expense of short-term deterioration of the 
haemodynamic condition. 
The acute pharmacological effects of (3-blocking agents are completely different from 
their long-term effect. While the beta blockers can cause progression in the symptoms of heart 
failure and deterioration in left ventricular function at short-term, they can produce 
considerable symptomatic, haemodynamic and survival benefit at long-term. The rapid 
blockade of adrenerg mechanisms supporting heart function can be held responsible for 
unfavourable acute effects of these drugs. The favourable influence on the cardiomyocytes by 
discontinuing or decreasing the harmful effect of the chronically elevated sympathetic tone 
can be the background of the long-term benefit. The gradual improvement in contractility (36) 
and in left ventricular ejection fraction demonstrated by several investigators (3,5,11,13,20) 
can be explained by this beneficial biological effect on cardiomyocytes prevention of cell loss 
and restoration of cell function. Nowadays more and more evidence indicates that (3-blockade 
improves not only the systolic but the diastolic left ventricular function (36) as well. 
It is not surprising that the improvement in left ventricular function is in close 
connection with the survival benefit of beta blockers (3,5,12,20,23). Several data suggest that 
a beneficial survival effect of beta adrenoreceptor blocker can be experienced only in patients 
whose left ventricular function, particularly left ventricular ejection fraction improves and where 
the reverse remodelling appears (5,20). Reverse remodelling occurs primarily through a decrease 
in left ventricular end-systolic diameter and it is characteristic almost exclusively of beta blockers. 
Carvedilol in the MOCHA trial (23) produced a dose-related increase in left ventricular 
ejection fraction and it was associated with near mirror-image reduction of mortality. A similar 
association was reported previously in a smaller study: the change in the left ventricular ejection 
fraction appeared to be a valuable parameter in defining the prognosis of patients with dilated 
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cardiomyopathy treated with metoprolol (5). Moreover, the substudy of 160 patients from the 
Cardiac Insufficiency Bisoprolol Study population showed that long-term mortality increased for 
subjects whose left ventricular fractional shortening decreased over 5 months if patients were 
treated with bisoprolol (20). 
Consequently, the early identification of patients whose left ventricular ejection fraction 
will not improve during beta blocker therapy seems to be of great importance. 
Although data regarding the predictive value for long-term outcome of heart failure are so 
far available only for the intermediate-term alteration in left ventricular ejection fraction (20,23), it 
appears to be well established that the intermediate-term change of other essential parameters 
such as the mean pulmonary capillary wedge pressure, and at least in treatment with 
cardioselective beta blockers, NYHA functional class and maximal exercise capacity can have 
an importance in the prediction of final outcome as well. The deterioration of these latter 
parameters in spite of 6 months of therapy raises doubt concerning the beneficial effect of the 
given drug on long-term prognosis of heart failure. That is why elaborating methods not only 
for prediction of intermediate-term changes of left ventricular ejection fraction may have 
clinical significance. 
In our follow-up, in both the derivation and validation group of patients the changes of the 
parameters characterising clinical and haemodynamic condition and left ventricular function 
during bisoprolol therapy were consistent with the previous favourable observations from 
uncontrolled and controlled studies in chronic heart failure (1-4,11-12,20,21,27,37-39). As 
regards the intermediate-term changes of the four essential parameters which were to be 
predicted, the use of bisoprolol led to improvement in clinical symptoms, increased left 
ventricular ejection fraction and maximal exercise capacity and decreased mean pulmonary 
capillary wedge pressure. It is noteworthy that some tendency of improvement was already 
seen in the case of almost every investigated parameter at short-term. The beneficial 
haemodynamic effect associated with marked decrease in heart rate (91 - > 6 7 min"1 in the 
derivation sample and 93 -> 67 min"1 in the validation group of patients) from its high 
baseline value and possibly the aggressive pre-study vasodilator treatment can provide 
explanations. However, there was a further improvement in all of the previous parameters at 
the 6 months analysis. 
With one exception, patients in both validation and derivation group tolerated the 
initiation and the maintenance of the treatment with bisoprolol. The low percent of intolerance 
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observed in our study can reflect the generally moderate grade of heart failure and the careful 
pre-study optimisation of vasodilator and diuretic treatment. 
In the derivation sample one patient died suddenly at the beginning of the titration 
phase. In the validation group one patient died due to progression of heart failure after the 
titration period, in the first month of the maintenance phase of the treatment. 
Predictors of intermediate-term change in left ventricular ejection fraction 
Improvement in left ventricular ejection fraction has consistently been reported after 
treatment with beta blockers in patients with heart failure (4,7,11,13,20,40). Moreover, that 
improvement proved to be dose-related: greater benefit was produced by higher dosages of beta 
blockers (20,39,40). Baseline left ventricular ejection fraction evaluated by radionuclide 
ventriculography (41) and its intermediate-term changes after different drug therapy were 
found to be significant predictors of the final outcome of chronic heart failure 
(4,12,20,23,42,43). 
The short-term change in pressure-rate product and baseline value of left ventricular 
ejection fraction proved to be significant multivariate predictors of intermediate-term change of 
left ventricular ejection fraction in our study. The greater the short-term decrease in the pressure-
rate product and the lower the value of the left ventricular ejection fraction at baseline, the more 
positive the response to bisoprolol. 
The short-term decrease in pressure-rate product reflects the short-term decrease of heart 
rate and systolic blood pressure. While the heart rate at baseline indicates the extent of 
sympathetic activity, the short-term decrease in heart rate and systolic blood pressure shows the 
decrease in sympathetic drive that can be achieved by short-term administration of beta blocker. 
The overwhelming predictive value of the short-term decreases in pressure-rate product may 
indicate that the patients with higher reduction of sympathetic drive at short-term react more 
favourably to beta blocker therapy. Considerable decrease in pressure-rate product accompanies 
pronounced decrease in myocardial oxygen demand and reduction of the chronic energy depletion 
of cardiomyocytes in heart failure. The more complete restoration of the energy balance can 
presumably influence the long-term prognosis beneficially. 
The progressively higher degree of sympathetic activation when the left ventricular dysfunction is 
more pronounced (44) can explain why the positive impact of beta-blocker treatment is higher in 
patients with more deteriorated left ventricular ejection fraction. 
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Many investigators have observed that patients with very low (14,19,21) and nearly normal 
(21) left ventricular ejection fraction do not respond optimally to beta blocker treatment. The 
explanation of these observations may be that in the patients with considerably impaired left 
ventricular function the amount of viable myocytes is too low for the manifestation of the 
beneficial effect (27). On the other hand the nearly normal ejection fraction may be 
accompanied by only slightly elevated sympathetic activation. 
The close correlation observed in our study between the left ventricular ejection fraction at 
baseline and the 6 months changes in this parameter can be explained on the one side by the 
absence of patients with very low and on the other by nearly normal left ventricular ejection 
fraction. The values of left ventricular ejection fraction at baseline were ranged between 20 and 40 
%. 
A less severe grade of heart failure, more aggressive vasodilator treatment and the 
absence of patients with elevated systolic blood pressure (the values of the systolic blood 
pressure at baseline in the derivation group of patients were ranged between 80 and 135 
mmHg) can explain why, unlike some other observations (21,26), the systolic blood pressure 
did not show any predictive value in our study. 
Exclusion of patients with heart rate lower than 70 beats/min may explain why, in 
disagreement with earlier metoprolol studies (24,25), we did not find the baseline heart rate to 
be predictive regarding left ventricular ejection fraction. Similar results were obtained from 
CIBIS I and CIBIS II studies by Lechat et al. (20,45). But it is known that only patients whose 
heart rate was higher than 65/min were included in the CIBIS studies. 
In our own previous study (28), where patients' baseline parameters reflected more 
severe clinical condition and the therapy applied differed from the therapy given in this study, 
in addition to the baseline value of left ventricular ejection fraction and short-term change in 
the pressure-rate product, the short-term change in the pulse amplitude proved to be a 
significant predictive factor, as well. This latter parameter proved not to be predictive in this 
study by multiple regression analysis but it was a borderline significant predictor by 
univariate regression analysis. 
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Predictors of intermediate-term change in mean pulmonary capillary wedge 
pressure 
Mean pulmonary capillary wedge pressure is mainly determined by the left ventricular 
diastolic function, however, in chronic heart failure frequently occurring mitral regurgitation is 
also an important determinant. 
Similarly to observations with other beta blockers (7,13,18), mean pulmonary capillary 
wedge pressure decreased after intermediate-term treatment with bisoprolol in our study. 
The mean pulmonary capillary wedge pressure has been repeatedly reported as a 
significant predictor of outcome of chronic heart failure in the effect of different drug therapy 
(39,42,46,47). Results of those studies showed that the higher the value of mean pulmonary 
capillary wedge pressure, the worse the long-term prognosis of chronic heart failure. 
Generally, the therapy decreasing the pathologically high mean pulmonary capillary wedge 
pressure improves the prognosis, too (48,49). 
Concerning the as yet not demonstrated predictive value of intermediate-term change of 
mean pulmonary capillary wedge pressure for long-term outcome during treatment with a beta 
blocker, it is a reasonable presumption that the gradual decrease in mean pulmonary capillary 
wedge pressure can be the consequence of the same positive biological effect of beta blockers on 
cardiomyocytes which favourably affects the survival of the patients as well. 
To date, only one study (26) has attempted to determine which patients have the highest 
diastolic function improvement with beta blockade. In this investigation the baseline left 
ventricular end-diastolic pressure was an independent predictor of change of left ventricular end-
diastolic pressure. In other studies, mean pulmonary capillary wedge pressure or variables closely 
related to it were only components of complex improvement indexes (11,21). 
According to our earlier data (28) the six-month effect of bisoprolol on mean pulmonary 
capillary wedge pressure related positively to the baseline value of mean pulmonary capillary 
wedge pressure and heart rate and negatively to the increase in heart rate during maximal exercise. 
In this study treating patients with bisoprolol the intermediate-term change in mean 
pulmonary capillary wedge pressure could be predicted from its short-term change. The positive 
correlation obtained shows, that a higher decrease in mean pulmonary capillary wedge pressure at 
short-term goes together with more pronounced decrease in mean pulmonary capillary wedge 
pressure at intermediate-term. Not easy to explain this finding. One can speculate that longer-term 
positive effect in respect of mean pulmonary capillary wedge pressure can be awaited if the well 
known immediate effect of beta blockers, such the reduction of heart rate and decrease in the 
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myocardial ischaemia, affect the mean pulmonary capillary wedge pressure positively already in 
the early phase of treatment. The substantial reduction in a high heart rate can result in several 
favourable changes already at short-term: it decreases myocardial ischaemia, improves the left 
ventricular diastolic relaxation, enhances the contractility and ejection performance of the 
myocardium. 
It is worth noting, that in our study the mean pulmonary capillary wedge pressure 
decreased already at 1 month treatment with bisoprolol. This early positive effect can be attributed 
at least partly to such immediate pharmacological effect as the heart rate reducing property of the 
beta blockers. 
The early decrease in mean pulmonary capillary wedge pressure indicating reduction the 
left ventricular wall tension and going together with improvement in myocardial oxygen balance 
may have a role in the later appearing beneficial alteration of cardiomyocytes. 
Adding this early positive haemodynamic effect to the later appearing beneficial biologic 
effect on the cardiomyocytes can result in greater decrease in mean pulmonary capillary wedge 
pressure at intermediate-term treatment of patients. 
Predictors of intermediate-term changes in NYHA functional class 
There are numerous reports, coinciding with the clinical experiences, which verify that the 
clinical grade of heart failure (NYHA class) is predictive for the long-term outcome of chronic 
heart failure (46,47,50). Treatment, with the exception of positive inotropes, decreasing the 
clinical grade of heart failure increases the chance of survival of the patients as well. 
The intermediate-term effect of beta blockers on NYHA class seems to be different 
according to their cardioselectivity. Contrary to the consistently recorded benefit when treating 
patients with cardioselective drugs (4,11,12,39), in the intermediate-term effect of non-selective 
preparations the improvement in NYHA class is less common and more moderate (16,40). The 
beneficial effect of bisoprolol recorded in our study is in accord with the effect of other 
cardioselective beta blockers. The time course of the change of NYHA class, the gradually 
appearing benefit is consistent with the theory that the favourable clinical effect is the 
manifestation of the positive biological effect of the drug on cardiomyocytes. This positive 
biological effect becomes evident gradually as the improvement in parameters characterising 
haemodynamic condition, left ventricular function and global clinical state. 
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Baseline NYHA class and heart rate were found to be valuable predictors of the 
intermediate-term changes in NYHA functional class by univariate and multiple regression 
analysis. 
The higher sympathetic activity, when the clinical grade of heart failure is more severe 
and the heart rate is high, and the observation that the effect of beta-blockers (such as 
bisoprolol) is more pronounced in the case of high sympathetic activity before beta blocker 
therapy, can be an acceptable explanation for the predictive value of the above parameters. 
According to the results of some studies, less benefit can be expected if heart failure is more 
severe (19,21). In this respect it is important to emphasise that patients included in our study 
had symptoms corresponding to class II or III of the New York Heart Association. 
Predictors of intermediate-term change in maximal exercise capacity 
Maximal exercise capacity has predicted the final outcome in chronic heart failure in 
many studies (47,51,52,53). Drug treatment with favourable effect on long-term outcome, not 
causing neuroendocrine activation, mostly increases exercise capacity as well. Although the 
effect of beta blockers on maximal exercise capacity, particularly the effect of non-selective 
preparations, can dissociate from the beneficial effect on the left ventricular function. 
Contrary to our positive result, bisoprolol did not increase symptom-limited exercise capacity 
in one study (48). The lack of effect of beta blockers on symptom-limited exercise capacity 
despite benefit on left ventricular function can be explained by the beta blockade-induced 
limitation of the heart rate and the cardiac index at maximal exercise. This effect is the most 
pronounced when using non-selective drugs causing complete beta blockade. The data on the 
effect of cardioselective beta-blockers on maximal exercise capacity are contradictory 
(11,12). 
Our uncontrolled data showed that the intermediate-term treatment with bisoprolol 
considerably improved the maximal exercise capacity. The explanation for this can be the 
increase of heart rate reserve in spite of the lower heart rate at maximal level of exercise, 
improvement of left ventricular systolic and diastolic function and the absence of blockade of 
P2 receptors in the peripheral arteries. 
In our study the intermediate-term change in maximal exercise capacity could be closely 
predicted from the baseline value of the maximal exercise capacity and NYHA functional 
class. The higher the value of the NYHA class and the lower the value of the maximal 
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exercise capacity at baseline, the more beneficial the effect of bisoprolol can be expected on 
maximal exercise capacity at intermediate-term. 
The more favourable beta blocker effect when the sympathetic activation is high can 
explain that observation. More severe heart failure and more decreased maximal exercise 
capacity can indicate patients with higher sympathetic activity. 
Applicability of the predictive model, prospective validation 
In our study the predictive model elaborated to predict the 6 months effect of bisoprolol on 
left ventricular ejection fraction, mean pulmonary capillary wedge pressure, NYHA functional 
class and maximal exercise capacity seems to be particularly valuable regarding prediction of the 
changes in left ventricular ejection fraction and NYHA functional class. This is indicated by the 
outstandingly high negative predictive accuracy connected with the prediction of the left 
ventricular ejection fraction and high positive predictive accuracy connected with the prediction 
of NYHA functional class. Using this predictive model it seems to be possible to predict reliably 
the patients whose left ventricular ejection fraction will deteriorate or remain unchanged after 6 
months of bisoprolol therapy. Similarly we can choose with outstanding accuracy before the 
introduction of bisoprolol, the patients whose clinical condition will improve during 6 months of 
bisoprolol treatment. 
The possibility to predict reliably the patients whose ejection fraction will not improve 
during 6 months of bisoprolol administration can be regarded as the greatest success of the 
predictive model described in this paper. Previous data show that the deterioration of the left 
ventricular systolic function during intermediate-term (5-6 months) treatment with beta blockers 
is accompanied by an increase in mortality (20). Thus the reliable prediction of "no improvement" 
of the left ventricular ejection fraction at intermediate-term treatment with beta blocker can select 
accurately after short-term treatment the patients for whom the beneficial survival effect of 
bisoprolol will be uncertain. Accordingly, in these cases an opportunity presents to discontinue or 
modify the therapy with beta blockers, change to an other beta blocker (54) or to follow up these 
selected patients more closely. 
In the validation group of patients the high value of sensitivity, specificity, positive and 
negative predictive accuracy in the case of left ventricular ejection fraction and NYHA functional 
class shows that the predictive model derived from the derivation sample is applicable to all 
patients characterised by the inclusion and exclusion criteria of this study. 
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Limitations of the study 
There is a limited applicability of the results for the whole spectrum of heart failure 
population as only patients with dilated cardiomyopathy were studied, the clinical grade of heart 
failure was mostly mild to moderate, and mainly men were investigated. The number of patients 
in both derivation and validation sample was limited. The results need to be verified in a larger 
patient population including patients with more severe heart failure too and not only patients with 
dilated cardiomyopathy but also to ischaemic heart disease as well as enrolment of women in an 
adequate proportion is needed. It should also be emphasised that our observations cannot be 
automatically extrapolated to other beta blockers, especially to carvedilol that differs in many 
respects from bisoprolol. 
Despite these limitations and the preliminary status of the findings, the present study 
can be of significance as a first step towards further investigations aiming to increase the 
therapeutic effectiveness of beta blockers in heart failure 
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Conclusions 
1. The well-known, favourable effects of beta blocker therapy when treating patients with 
chronic heart failure, i.e. the increase in left ventricular ejection fraction, the decrease in mean 
pulmonary capillary wedge pressure, the improvement of NYHA functional class and 
maximal exercise capacity were reproducible in 48 patients with dilated cardiomyopathy 
treated with bisoprolol for six months. 
2. By elaborating a predictive model and by validating it prospectively I was able to prove, that 
by application of simple, non-invasive parameters, used in the everyday clinical practice the 
intermediate-term (6-month) effects of bisoprolol on symptoms, on left ventricular systolic 
and diastolic function and maximal exercise capacity are predictable reliably. 
3. The model proved to be especially reliable for the early identification of the patients whose 
left ventricular ejection fraction did not improve after 6 months treatment with bisoprolol. 
According to previous data (Lechat et al. - Circulation 1997) by this way we can select the 
cases in whom the long-term favourable survival effect of bisoprolol is much too 
questionable. 
4. The model proved to be similarly reliable to identify those patients in whom the intermediate-
term treatment with bisoprolol resulted in significant clinical improvement, i.e. improvement 
in NYHA class. 
5. The predictive model elaborated in this study affords possibility the early identification of 
responders and non-responders to long-term bisoprolol treatment. Further investigation, closer 
follow up of non-responders and modification or early withdrawal of beta blocker treatment 
can increase the therapeutic potential of beta blocker therapy in chronic hear failure. 
31 
References: 
1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic 
receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36. 
2. Swedberg K, Waagstein F, Hjalmarson A, Wallentin I. Prolongation of survival in congestive 
cardiomyopathy by beta-receptor blockade. Lancet 1979; 1:1374-6. 
3. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-
blockade in congestive cardiomyopathy. Br Heart J 1980; 44:117-33. 
4. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term P-blockade in 
congestive cardiomyopathy : effects of short- and long-term metoprolol treatment followed by 
withdrawal and readmission of metoprolol. Circulation 1989; 80: 551-63. 
5. Engelmeier RS, CTConnell JB, Walsh RW, Rad N, Scanlon PJ, Gunnar RM. Improvement in 
symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a 
double-blind, randomised, placebo-controlled trial. Circulation 1985; 72: 536-46. 
6. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure 
caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84:2426-41. 
7. Dékány M., Vándor L., Sereg M., Nyolczas N., Balogh I., Fiók J.: Metoprolol kezelés 
dilatativ cardiomyopathiában. LAM 1991. 1 (18): 1290-1299. 
8. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middelmost S, Rothisberger C, 
Skudocky D, Sareli P. Long-term (3 month) effects of a new beta-blocker (nebivolol) on 
cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-1100. 
9. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol 
improves left ventricular function and symptoms in chronic heart failure: a double-blind 
randomized study. J Am Coll Cardiol. 1995; 25:1225-1231. 
32 
10. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term Carvedilol 
administration on rest and exercise hemodynamic variables, exercise capacity and clinical 
conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 
1678-1687. 
11. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, 
Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) 
Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. 
Lancet 1993; 342: 1441-6. 
12. CIBIS Investigators and Committees. A randomized trial of ß-blockade in heart failure: the 
Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:1765-73. 
13. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH; for 
the U.S. Carvedilol Heart Failure Study Group. The effect of Carvedilol on morbidity and 
mortality in patients with chronic heart failure. N Eng J Med 1996; 334:1349-55. 
14. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS 
II): a randomised trial. Lancet 1999; 353: 9-13. 
15. MERIT HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol 
CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 
1999; 353:2001-07. 
16. M Packer, A Coats, M Fowler, H Katus, H Krum, P Mohacsi, J Rouleau, M Tendera, A 
Castaigne, E Roecker, M Schultz, D DeMets for the Carvedilol Prospective Randomized 
Cumulative Survival Study Group. Effect of Carvedilol on survival in severe chronic heart 
failure. N Eng J Med 2001; 344: 1651-8. 
17. Funck-Brentano C, Lancar R, Le Heuzey JY, Lardoux H, Soubrie C, Lechat P. Predictors of 
medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study (CIBIS): A 
study of the interactions between ß-blocker therapy and occurrence of critical events using 
analysis of competitive risks. Am Heart J 2000; 139:262-71. 
33 
18. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P; on behalf of the CIBIS II 
Investigators. Sex differences in the prognosis of congestive heart failure. Results from the 
Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103: 375-380. 
19. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker 
bucindolol in patients with advanced chronic heart failure. N Eng J Med 2001; 344:1659-67. 
20. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel 
M, Jaillon P, Boissel JP, Mallet A, on behalf of the CIBIS Investigators. Prognostic value of 
bisoprolol-induced hemodynamic effects in heart failure during the cardiac insufficiency 
bisoprolol study (CIBIS). Circulation 1997; 96:2197-2205. 
21. Di Lenarda A, Gregori D, Sinagra G, Lardieri G, Perkan A, Pinamonti B, Salvatore L, Secoli 
G, Zecchin M, Camerini F, The Heart Muscle Disease Study Group. Metoprolol in dilated 
cardiomyopathy: Is it possible to identify factors predictive of improvement? J Card Fail 
1996; 2:87-102. 
22. Anderson JL. Treatment of cardiac myopathies with beta blockers. What do we know, where 
do we go from here? Postrgrad Med 1988; 29:104-12. 
23. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, 
Narahara KA, Ingersoll H, Krueger S, Young ST, Shusterman NH; for the MOCHA 
Investigators. Carvedilol produces dose-related improvements in left ventricular function and 
survival in subjects with chronic heart failure. Circulation 1996; 94:2807-2816. 
24. Schwartz BM, Sackner-Bernstein J, Penn J, Krum H, Medina N, Yushak M, Goldsmith RL, 
Kukin ML, Packer M. Which patients with chronic heart failure are most likely to show 
hemodynamic and functional improvement following long-term beta-blockade? J Am Coll 
Cardiol 1992; 19: 341A. 
25. Bennett SK, Fisher ML, Krichten C, Patten RD, Greenberg NL, Gottlieb SS. Ischaemic 
cardiomyopathy treated with metoprolol: baseline heart rate predicts likelihood of increased 
ejection fraction. Circulation 1993; 88 (suppl I): 1-105. 
34 
26. Eichhorn EJ, Heesch CM, Risser RC, Marcoux L, Hatfield B. Predictors of systolic and 
diastolic improvement with dilated cardiomyopathy treated with metoprolol. J Am Coll 
Cardiol 1995; 25: 154-62. 
27. Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Minamino T, 
Tsijimura E, Nagareda T, Kotoh K, Hoki N. Which subgroup of patients with dilated 
cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. 
J Am Coll Cardiol 1993; 89: 1632-42. 
28. Nyolczas N, Dékány M, Fiók J, Préda I. Prediction of the effect of bisoprolol in dilated 
cardiomyopathy. Cardiovascular Drugs and Therapy 2000; 14: 543-550. 
29. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and 
methodological standards. N Engl J Med 1985; 313: 793-9. 
30. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J for the 
Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17. 
31. WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 
1980; 44:672-3. 
32. Dékány M, Vándor L, Kékes E, Reif É, Berentey E, Antalóczy Z. Estimation of left atrial 
filling pressure by apexcardiography. Reliability of new parameters. Acta Cardiol 1990; 2: 
113-20. 
33. Mortarino G, Ghiringhelli S, Onofri M, Macchi G, Corda G. Apexcardiographic evaluation of 
wedge pressure. Acta Cardiol 1985; 40:119-22. 
34. Quinones MA, Mokotoff DM, Nouri S, Winters WL, Miller RR. Noninvasive quantification 
of left ventricular wall stress. Validation of method and application to assessment of chronic 
pressure overload. Am J Cardiol 1980; 45: 782-790. 
35 
35. Draper N, Smith H. Applied Regression Analysis, 2nd ed. New York: John Wiley, 1981. 
36. Eichhorn DJ, Bedotto JB, Malloy CR et al. Effect of ß-adrenergic blockade on myocardial 
function and energetics in congestive heart failure. Circulation 1990; 82: 473-83. 
37. Eichhorn EJ. Effects of bucindolol in heart failure. Am J Cardiol 1993; 71: 65C-70C. 
38. Heilbrunn SM, Shah P, Bristow MR, Valentine HA, Ginsberg R, Fowler MB. Increased ß-
receptor density and improved hemodynamic response to catecholamine stimulation during 
long-term metoprolol therapy in heart failure from dilated cardiomyopthy. Circulation 1989; 
79: 483-90. 
39. Di Lenarda A, De Maria R, Gavazzi A, Gregori D, Paralini M, Sinagra G, Salvatore L, 
Longaro F, Bemobich E, Camerini F, on behalf of the SPIC (Italian Multicentre 
Cardiomyopathy Study) Group. Long term survival effect of metoprolol in dilated 
cardiomyopathy. Heart 1998; 79: 337-344. 
40. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-
controlled trial of Carvedilol in patients with congestive heart failure due to ischaemic heart 
disease. Lancet 1997; 349: 375-80. 
41. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart 
failure. Eur Heart J 1998; 19: 696-710. 
42. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic 
dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903-8. 
43. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide 
dinitrate in the treatment of chronic heart failure. N Eng J Med 1991; 325: 303-10. 
44. Francis GS, Benedict C, Johnstone DE, et al. for the SOLVD Investigators. Comparison of 
neuroendocrine activation in patients with left ventricular dysfunction with and without 
congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). 
Circulation 1990; 82: 1724-1729 
36 
45. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen -Grandjean M, 
Pochmalicki G, Dargie H on behalf of the CIBIS II Investigators. Heart rate and cardiac 
rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS 13 trial. 
Circulation 2001; 103: 1428-1433. 
46. Campana C, Gavazzi A, Berzuini C et al. Predictors of prognosis in patients awaiting heart 
transplantation. Jnl Heart Lung Transpl 1993; 12: 756-65. 
47. Nyolczas N, Dékány M, Reif É, Vándor L, Fiók J, Préda I. Terheléses vizsgálati paraméterek 
és egyszerű, noninvazív bal kamra funkciós változók prognosztikus értéke dilatatív 
cardiomyopathiában. OrvHetil 1995; 136: 1763-68. 
48. Fonarow GC, Chelimsky-Fallick C, Stevenson LW et al. Effect of direct vasodilation with 
hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in 
advanced heart failure: The Hy-C trial. J Am Coll Cardiol 1992; 19: 842-50. 
49. Stevenson LW, Tillisch JH, Hamilton M et al. Importance of haemodynamic response to 
therapy in predicting survival with ejection fraction < 20 % secondary to ischaemic or 
nonischaemic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1348-54. 
50. Bart BA, Shaw LK, McCants CB et al. Clinical determinants of mortality in patients with 
angiographically diagnosed ischemic or nonischemic cardiomyopathy.! Am Coll Cardiol 
1997; 30: 1002-8. 
51. Aaronson KD, Schwartz JS, Chen T, Wong K, Goin JE, Mancini DM. Development and 
prospective validation of a clinical index to predict survival in ambulatory patients 
referred for cardiac transplant evaluation. Circulation 1997; 95: 2660-7. 
52. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic 
congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. 
Am J Cardiol 1987; 59: 634-8. 
37 
53. Dékány M, Nyolczas N, Reif É, Fiók J, Vándor L, Paksy A. Prognostic value of simple 
exercise test parameters in patients with dilated cardiomyopathy. Acta Cardiol 1995; 50: 
45-52. 
54. Di Lenarda A., Sabbadini G., Salvatore L., Sinagra G., Mestroni L., Pinamonti B., Gregori 
D., Ciani F., Muzzi A., Klugmann S., Camerini F. Long-term effect of Carvedilol in 
idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite 
chronic metoprolol. The Heart-Muscle Disease Study Group. JACC 1999; 33(7): 1926-34. 
38 
Table 1. Clinical characteristics observed at baseline in the derivation and validation 
patient groups and their comparison 
Derivation group Validation group P 
Age (years) 53.8 ±15.9 50.4 ±17.6 N.S. 
Gender (males %) 91 95 
MEC (kJ) 49.7 ±25.7 51.3 ±28.2 N.S. 
LVEF(%) 32.6 ±6.4 30.8 ±6.5 N.S. 
mPCW (mmHg) 19.3 ±7.5 20.5 ± 8.3 N.S. 
NYHA class 2.47 ± 0.45 2.53 ±0.34 N.S. 
HR (min"1) 90.9 ± 17.0 93.4 ± 15.7 N.S. 
BPs (mmHg) 110.3 ± 17.7 105.4 ± 15.5 N.S. 
Therapy % 
ACE inhibitor 100 100 
Spironolactone 100 100 
Diuretic 100 100 
Digoxin 74 72 
MEC: maximal, exercise capacity, LVEF: left ventricular ejection fraction, mPCW: mean 
pulmonary capillary wedge pressure, NYHA class: New York Herat association functional 
class, HR: heart rate, BPs: systolic blood pressure 
N.S.: non-significant 
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Table 2a Effect of 6 months of bisoprolol treatment in the derivation sample 
Baseline value After 1 month of 
treatment 
After 6 months of 
treatment 
HR (min1) 90.9 ± 17.0 67.2 ± 9.4a 62.6 ± 10.6a 
BPs (mmHg) 110.3 ± 17.7 104.1 ±11.2 N.S. 118.8 ± 13.6d 
PP (mmHg) 35.6 ±8.5 33.5 ±9.3 N.S. 42.4 ± 11.lb 
PRP (mmHg x min"1) 9952.9 ±2137.7 6980.6 ± 1152.4a 7199.4 ± 1400.5a 
LVEF (%) 32.6 ±6.4 34.2 ±9.9 N.S. 42.6 ± 10.1a 
mPCW (mmHg) 19.3 ±7.5 16.3 ±9.7 N.S. 13.8 ± 7.2b 
NYHA class 2.47 ± 0.45 2.06 ± 0.58a 1.68 ± 0.47a 
MEC (kJ) 49.7 ± 25.7 60.2 ± 27.3 d 75.9 ± 35.8a 
AHRmax (min1) 55.5 ±22.9 54.4 ±21.3 N.S. 58.3 ±23.1 N.S. 
ESWT (mmHg) 323.0 ± 135.0 271.7 ±57.7 N.S. 284.1 ± 162.4d 
ESWT x HR (mmHg x min"1) 28930.4 ± 11696.0 18132.4 ±3998.2b 17609.4 ± 9675.0a 
a p< 0.001 
bp < 0.005 
cp<0.01 
dp < 0.05 
N.S.: non-significant 
HR: heart rate, BPs: systolic blood pressure, PP: pulse pressure, PRP: pressure-rate product, 
LVEF: left ventricular ejection fraction, NYHA class: New York Heart Association functional 
class, MEC: maximal exercise capacity, AHRmax: the increase in heart rate from rest to 
maximal level of exercise, ESWT: end-systolic wall tension, ESWT x HR: the product of end-
systolic wall tension and heart rate 
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Table 2b. Effect of 6 months of bisoprolol treatment in the validation group 
Baseline value After 1 month of 
treatment 
After 6 months of 
treatment 
HR (min1) 93.4 ± 15.7 66.9 ± 10.8a 65.5 ± 11.28 
BPs (mmHg) 105.4 ± 15.5 100.8 ±9.3 N.S. 114.5 ± 16.2d 
PP (mmHg) 30.3 ± 8.9 31.4 ± 10.1 N.S. 40.9 ± 10.4° 
PRP (mmHg x min"1) 9885.0 ± 1930.1 6725.4 ± 1240.7a 7232.6 ± 1434.5a 
LVEF (%) 30.8 ±6.5 33.8 ±9.9 N.S. 41.6 ± 9.5a 
mPCW (mmHg) 20.5 ± 8.3 18.1 ±8.8 N.S. 14.4 ± 6.4a 
NYHA class 2.53 ±0.34 2.14 ± 0.48a 1.74 ± 0.36a 
MEC (kJ) 51.3 ±28.2 65.9 ± 25.9d 74.6 ± 35.2a 
AHRmax (min1) 49.3 ± 22.8 47.9 ±21.4 N.S. 54.2 ±23.2 N.S. 
ESWT (mmHg) 299.3 ± 64.7 269.8 ± 59.3 d 256.4 ± 82.9d 
ESWT x HR (mmHg x min1) 27166.6 ±6349.5 17843.2 ± 3982.3a 16017.8 ± 5944.4a 
a p< 0.001 
bp < 0.005 
cp < 0.01 
dp < 0.05 
N.S.: non-significant 
HR: heart rate, BPs: systolic blood pressure, PP: pulse pressure, PRP: pressure-rate product, 
LVEF: left ventricular ejection fraction, NYHA class: New York Heart Association functional 
class, MEC: maximal exercise capacity, AHRmax: the increase in heart rate from rest to 
maximal level of exercise, ESWT: end-systolic wall tension, ESWT x HR: the product of end-
systolic wall tension and heart rate 
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Table 3. Effect of 6 months of bisoprolol treatment on the parameters to be predicted 
in the derivation group 
Baseline value 
After 6 months of 
bisoprolol treatment 
Change after 6 
months of bisoprolol 
treatment* 
P< 
NYHA class 2.47 ±0.45 1.68 ±0.47 -0.79 ± 0.61 0.001 
LVEF 32.6 ± 6.4 % 42.6 ± 10.1 % 37.0 ± 42.8 % 0.001 
mPCW 19.3 ± 7.5 mmHg 13.8 ±7.2 mmHg -28.8 ±33 .6% 0.005 
MEC 49.7 ± 25.7 kJ 75.9 ± 35.8 kJ 73.6 ±78 .4% 0.001 
(* The change after 6 months of bisoprolol treatment in NYHA class was expressed in 
absolute value, while the changes in left ventricular ejection fraction, mean pulmonary 
capillary wedge pressure and maximal exercise capacity were expressed as a percentage of the 
baseline value.) 
NYHA class: New York Heart Association functional class, LVEF: left ventricular ejection 
fraction, mPCW: mean pulmonary capillary wedge pressure, MEC: maximal exercise 
capacity 
42 
Table 4. Results of the univariate regression analysis 
Variable to be 
predicted 
Predictor parameter r P 
ALVEF % LVEFa -0.570 0.017 
p p b -0.413 0.100 
PRPb -0.409 0.100 
AmPCW % ESWT" -0.556 0.031 
mPCWb 0.522 0.046 
ESWT x HRa -0.498 0.059 
ESWTb 0.463 0.082 
ESWT x HRb 0.491 0.063 
ANYHA class NYHA class" -0.656 0.004 
HRa -0.579 0.015 
AMEC % NYHA class" 0.571 0.021 
MEC" -0.564 0.023 
mPCW" 0.552 0.041 
a Baseline values 
b Short-term changes (differences between the values of the parameters at short-term 
bisoprolol treatment and at baseline) 
r. coefficient of correlation 
ALVEF %: the change in left ventricular ejection fraction at intermediate-term 
expressed as a percentage of baseline value, AmPCW %: the change in mean pulmonary 
capillary wedge pressure at intermediate-term expressed as a percentage of baseline value, 
ANYHA: the change in New York Heart Association functional class at intermediate-term 
expressed as an absolute value, AMEC %: the change in maximal exercise capacity at 
intermediate-term expressed as a percentage of baseline value 
LVEF: left ventricular ejection fraction, PP: pulse pressure, PRP: pressure-rate 
product, ESWT: end-systolic wall tension, mPCW: mean pulmonary capillary wedge 
pressure, ESWT x HR: the product of end-systolic wall tension and heart rate, NYHA class: 
New York Heart Association functional class, HR: heart rate, MEC: maximal exercise 
capacity 
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Table 5. Results of multiple regression analysis 
Variable to be Predictor 
predicted variables B P P 
ALVEF % 
LVEFa 
PRPb 
-3.001 
-0.0099 
0.002 
0.012 
0.002 
AmPCW % mPCW" 2.400 0.046 0.046 
ANYHA class HRa -0.014 0.072 0.004 
NYHA class3 -0.692 0.021 
AMEC % MECa -1.159 0.138 0.025 
NYHA class3 68.427 0.125 
a Baseline values 
b Short-term changes (differences between the values of the parameters at short-term 
bisoprolol treatment and at baseline) 
B: coefficient 
ALVEF %: the change in left ventricular ejection fraction at intermediate-term 
expressed as a percentage of baseline value, AmPCW %: the change in mean pulmonary 
capillary wedge pressure at intermediate-term expressed as a percentage of baseline value, 
ANYHA: the change in New York Heart Association functional class at intermediate-term 
expressed as an absolute value, AMEC %: the change in maximal exercise capacity at 
intermediate-term expressed as a percentage of baseline value 
LVEF: left ventricular ejection fraction, PRP: pressure-rate product, mPCW: mean 
pulmonary capillary wedge pressure, HR: heart rate, NYHA class: New York Heart 
Association functional class, MEC: maximal exercise capacity 
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Table 6. Sensitivity, specificity, positive and negative predictive accuracy of the predictive 
model in the derivation group 
LVEF mPCW NYHA class MEC 
Number of true 12 12 15 12 
positive cases 
Number of false 3 3 0 6 
positive cases 
Number of true 8 6 5 2 
negative cases 
Number of false 0 2 3 3 
negative cases 
Sensitivity (%) 100.0 85.7 83.3 80.0 
Specificity (%) 66.7 66.7 100.0 25.0 
Positive predictive 80.0 80.0 100.0 66.7 
accuracy 
Negative predictive 100.0 75.0 62.5 40.0 
accuracy 
Total error rate 
(%) 
13.0 21.7 13.0 39.0 
LVEF: left ventricular ejection fraction, mPCW: mean pulmonary capillary wedge pressure, 
NYHA class: New York Heart Association functional class, MEC: maximal exercise capacity 
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Table 7. Sensitivity, specificity, positive and negative predictive accuracy of the predictive 
model in the validation group 
LVEF mPCW NYHA class MEC 
Number of true 11 11 14 12 
positive cases 
Number of false 3 3 1 4 
positive cases 
Number of true 7 6 4 2 
negative cases 
Number of false 1 2 3 4 
negative cases 
Sensitivity (%) 91.7 84.6 82.4 75.0 
Specificity (%) 70.0 66.7 80.0 33.3 
Positive predictive 78.6 78.6 93.3 75.0 
accuracy 
Negative predictive 87.5 75 57.1 33.3 
accuracy 
Total error rate (%) 18.2 22.7 18.2 36.4 
LVEF: left ventricular ejection fraction, mPCW: mean pulmonary capillary wedge pressure, 
NYHA class: New York Heart Association functional class, MEC: maximal exercise capacity 
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Figure 1/a 
Changes in LVEF% in derivation 
sample at intermediate-term 
Figure 1/b 
Changes in L V E F % in validation 
sample at intermediate-term 
Changes in LVEF% (predicted) 
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Figure 1/a 
Figure 2/b 
Changes in LVEF% in derivation 
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Figure 1/a 
Changes in LVEF% in derivation 
sample at intermediate-term 
Changes in MEC% (predicted) 
Figure 4/b 
Changes in M E C % in validation 
sample at intermediate-term 
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